PartyBoy
-
Total Posts
:
26473
-
Reward points
:
8182
- Joined: 14/01/2003
- Location: The North, UK
-
Status: offline
- Read my TROG
|
RE: Clenbuterol
19 May 2005 22:05
( permalink)
Study suggesting strong down regulation of beta-2's in mice after 12 days: Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R317-22. A farnesyltransferase inhibitor attenuated beta-adrenergic receptor downregulation in rat skeletal muscle. Lavoie JL, Calderone A, Beliveau L. Departement de Kinesiologie, Universite de Montreal, Montreal, Quebec, Canada H3C 3J7. Farnesylation represents an essential posttranslational modification of several well-defined proteins implicated in the homologous desensitization of the beta-adrenergic receptor (beta-ADR). The following study examined the effect of a novel farnesyltransferase inhibitor, BMS-191563, on agonist-mediated beta-ADR downregulation in skeletal muscle. Female Sprague-Dawley rats were treated for 12 days with the beta2-adrenergic agonist clenbuterol (4 mcg/kg) with or without the concurrent administration of BMS-191563 (2 mg x kg(-1) x day(-1)). Clenbuterol promoted gastrocnemius muscle hypertrophy, whereas the soleus muscle was unaffected. Total beta-ADR density was decreased by 45 and 40% in the soleus and medial gastrocnemius (MG), respectively, after clenbuterol treatment. Extract taken from mindandmuscle.net (author "Loki") Given clen’s agonistic potency, and the differing molecular structure of the beta2 receptor as opposed to its beta1 and beta3 counterparts, it is only a matter of time in all chronic clenbuterol users before almost complete, system-wide desensitization of the beta2 receptor-class sets in (15,16). 15. M Zhao and KH Muntz Differential downregulation of beta 2-adrenergic receptors in tissue compartments of rat heart is not altered by sympathetic denervation Circulation Research, Vol 73, 943-951 16. Boldt Perioperative management of patients with impaired left ventricular function. Current Opinion in Anaesthesiology. 11(3):315-319, June 1998 ....The specific mechanisms responsible for adrenergic downregulation of the beta2 seem to be heavily G-protein implicated (18). More specifically, researchers speculate that the process begins with the uncoupling of the receptor’s heterotrimeric G after acute exposure to the agonist (19). Eventually, with enough chronic stimulation, the receptor/arrestin [note: arrestins are proteins which can bind or uncouple heterotrimeric G proteins from G protein-coupled receptors] complex, which would normally be recycled to the cellular membrane after exposure to the agonist is halted, is instead translocated to the lysosomes (20). Lysosomes, for those not aware, are essentially the unheralded cousins of the peroxisomes. While the peroxisomes tend to get all the shine because the PPARs are so pivotal in regulating metabolic substrate oxidation and adipocyte differentiation, the lysosomes are the guys who tend to handle the cellular ‘grunt work’—eating up bacteria, decaying organelles, and other byproducts your cell doesn’t really want hanging around in there. In this case, with chronic clenbuterol exposure, your cell doesn’t want your beta2 receptors hanging around anymore, and the lysosomes eventually just start taking them out, Mafioso-style, in a process known in “Whachu’ talkin’ bout Willis?†terms as ‘homologous desensitization.’ And, just like that, beta2-mediated lipolysis is suddenly closed for business. My. How the tables have turned. 18. Bouvier, M, and Rousseau G. Subtype-specific regulation of the -adrenergic receptors. Adv Pharmacol 42: 433-438, 1998 19. Fergurson, SSG, Zhang J, Barak LS, and Caron MG. G-protein-coupled receptor kinases and arrestins: regulators of G-protein-coupled receptor sequestration. Biochem Soc Trans 24: 953-959, 1996 20. Zhang, J, Barak LS, Anborgh PH, Laporte SA, Caron MG, and Ferguson SSG Cellular trafficking of G protein-coupled receptor/-arrestin endocytic complexes. J Biol Chem 274: 10999-11006, 1999 other "studies" - some more relative than others: Brain Res Bull. 1996;41(2):93-6. Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation. Newman-Tancredi A, Verriele L, Chaput C, Millan MJ. Department of Psychopharmacology, Institut de Recherches Servier, Paris, France. Desipramine (DMI, 15 mg/kg, s.c.) decreased [3H]CGP-12177-labelled cortical beta-adrenoceptor density (Bmax) by 30% upon chronic (14 day) treatment. However, even a single dose (in mg/kg) of DMI (15) or the beta-adrenoceptor agonist, clenbuterol (20), induced a rapid (24 hour) and significant reduction of beta-adrenoceptor Bmax (-15%; p < 0.01). Acute treatment with amitryptiline (10), clorgyline (1), fluoxetine (10), nomifensine (10) or maprotiline (20) had no significant effect on [3H]CGP-12177-labelled beta-adrenoceptors, suggesting that rapid down-regulation may not be a general property of antidepressant drugs. None of the antidepressants altered the Bmax of [3H]ketanserin-labelled 5-HT2A receptors on acute treatment. These results show that beta-adrenoceptor down-regulation by clenbuterol and DMI is not dependent on chronic treatment and may, therefore, be a poor correlate of the gradual onset of therapeutic efficacy seen clinically with antidepressant drugs -------------- Equine Vet J. 2002 Sep;34(6):587-93 Regulation of equine lymphocyte beta-adrenoceptors under the influence of clenbuterol and dexamethasone. Abraham G, Brodde OE, Ungemach FR. Institute of Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary Medicine, University of Leipzig, Germany. In 12 healthy horses, the effects of the beta2-agonist clenbuterol and the glucocorticoid dexamethasone on the lymphocyte beta2-adrenoceptor density and affinity (determined by (-)-[125I]-iodocyanopindolol binding) as well as its responsiveness (assessed by lymphocyte cyclic AMP [cAMP] responses to 10 micromol/l (-)-isoprenaline) were studied. Clenbuterol treatment, 2 x 0.8 microg/kg/day i.v. for 12 days, decreased significantly ICYP binding sites by approximately 30-40%; concomitantly, lymphocyte cAMP response to (-)-isoprenaline was reduced. After withdrawal of clenbuterol, beta2-adrenoceptor density and responsiveness gradually increased, reaching predrug levels after 4 days. The effects of dexamethasone on clenbuterol-induced desensitisation were further investigated. Administration of dexamethasone (1 x 0.1 mg/kg/day, i.v. for 5 days) immediately after clenbuterol withdrawal accelerated beta2-adrenoceptor recovery: only 24 h after administration dexamethasone restored the number of binding sites and cAMP response to (-)-isoprenaline to levels statistically indistinguishable from values before clenbuterol treatment. Three days after dexamethasone administration, lymphocyte beta2-adrenoceptors were further increased about 2-fold the pretreatment values, and this increase declined gradually after dexamethasone withdrawal, reaching baseline values after 4 days. Furthermore, in groups exposed simultaneously to both drugs, dexamethasone completely prevented clenbuterol-induced decrease in lymphocyte beta2-adrenergic receptor density and responsiveness. No significant change was observed in the dissociation constant for ICYP in any of the situations. We conclude that dexamethasone (glucocorticoids) can reverse and prevent Clenbuterol-induced desensitisation (down-regulation) of the lymphocyte beta2-adrenoceptors and therefore, a combined therapy with clenbuterol and dexamethasone may be potentially beneficial in horses suffering from chronic obstructive pulmonary disease (COPD). -------------- Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R317-22. Implications of feedback regulation of beta-adrenergic signaling S. E. Mills Department of Animal Science, Purdue University, West Lafayette, IN 47907 Pigs fed βAR ligands show a rapid response in growth and feed efficiency that tends to peak during the first 7 to 10 d but declines thereafter toward zero by approximately 6 wk. A similar pattern was reported in rats fed clenbuterol and was accompanied by a 50% reduction in βAR in skeletal muscle. Compensatory desensitization is a well-characterized response to chronically elevated agonist concentration that results in a net loss of beta-adrenergic receptors (βAR) from the plasma membrane and reduced tissue response. The ability of βAR agonists to affect pig growth and alter body composition may well be limited by βAR desensitization. Regarding the possibility of muscle anabolism from Clen, there are many studies to suggest that anaerobic and aerobic capacity are diminished following clenbuterol, which to me would indicate direct muscle/strength loss, or indirectly - possibly as a result of decreased cardiac function. However, as you'd expect, the results are often contratictory from such "studies". It has proved beneficial to mice with muscular dystrophy, yet deleterious to excercise performance in rats and mice: Dupont-Versteegen, E. et al. 1995. Muscle and Nerve. 18:1447-1459. Duncan, N.D. et al. 2000. Clinical Science. 98:339-347. Zeman, R.J. et al. 1994. Am. J. Physiol. 267:C865-C868. Ingalls, C.P. et al. 1996. J. Appl. Physiol. 80:795-801. -------------- Again, courtesy of mind and muscle, with references: Reductions in cardiac capacity and structure, as well as VO2max, also seem to be implicated (3). And although in some studies consistent exercise training has been able to counteract some of clen’s performance-reducing effects, the general scientific consensus remains that chronic clenbuterol treatment is directly antagonistic to exercise performance in animals (4). In non-asthmatic humans, there is very little to indicate that beta-agonist drugs will improve anaerobic or aerobic work capacity (5,6,7). 3. Kearns CF, McKeever KH. Clenbuterol diminishes aerobic performance in horses. Med Sci Sports Exerc. 2002 Dec;34(12):1976-85. 4. Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond). 2000 Mar;98(3):339-47. 5. Meeuwisse WH, Mckenzie DC, Hopkins SR, et al: The effect of salbutamol on performance in elite non-asthmatic athletes. Med Sci Sports Exerc 1992;24(10):1161-1166 6. Morton AR, Joyce K, Papalia SM, et al: Is salmeterol ergogenic? Clin J Sports Med 1996;6(4):220-225 7. Robertson W, Simkins J, O'Hickey SP, et al: Does single dose salmeterol affect exercise capacity in asthmatic men? Eur Respir J 1994;7(11):1978-1984
<message edited by PartyBoy on 19 May 2005 22:37>

|